The settlement of this federal securities fraud class action lawsuit is on behalf of investors who purchased or otherwise acquired Enochian Biosciences Inc. (“Enochian”) common stock between January 17, 2018 and June 27, 2022, inclusive (the “Class Period”).
Enochian agreed to pay $2,500,000 to resolve this class action lawsuit alleging the company and certain of its officers and/or directors violated federal securities laws by making false or misleading statements.
What’s the status of the Settlement?
On August 18, 2025, the Court granted Preliminary Approval of the Class Action Settlement. There was a Final Settlement Hearing on November 25, 2025, and the Motion for Final Approval is pending decision before the Court.
Who can file a claim?
The settlement class includes all persons or entities who:
- Purchased or otherwise acquired Enochian common stock between January 17, 2018 and June 27, 2022, inclusive.
How much is the Settlement Payment?
Pro rata payment: The total settlement fund is $2,500,000. The amount each class member receives will depend on several factors, including:
- The number of valid claims submitted
- The number of shares purchased and sold
- The dates of purchase and sale
- The price paid for the shares and the price received upon sale
How do I file a claim?
The deadline to file a claim was December 7, 2025. To submit a claim and/or to find additional information regarding the terms of the settlement and claim filing process, go to www.enochiansecuritieslitigation.com, or contact the claims administrator, Epiq Class Action & Claims Solutions, Inc., at 1-888-864-4860.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.